Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass

NCT00154427 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00154427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00154427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2004
Completion date
November 30, 2007
Enrollment
172 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

acquired bleeding disorder, cardiac surgery requiring cardiopulmonary bypass